Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy

Abstract

The invention relates to 3-, 5-, 7-trisubstituted pyrazolo[4,3-d]pyrimidines represented by the general formula I and pharmaceutically acceptable salts thereof, whereinR3 is an optionally substituted alkyl, cycloalkyl, cycloheteroalkyl, cycloalkyl alkyl, aryl or alkylaryl group;R5 is halogen, —NHNH, —NHOH, NHCONH, guanylo (NH—C(NH)NH) an optionally substituted C-Calkyl, alkenyl, alkynyl, C-Ccycloalkyl, R(C-Ccycloalkyl), heterocyclyl, heteroalkyl, aryl, heteroaryl, arylalkylene, arylalkenylene, arylalkynylene, cycloheteroalkyl, cycloheteroalkyl alkyl, heteroarylalkylene, heteroarylalkenylene, heteroarylalkynylene group, the group —C(O)—R, —C(O)NRR, —SOR, or —NHC(O)R, wherein Rand Rare an optionally substituted C-Calkyl, alkenyl, or alkynyl group, R, R, and Rare independently selected from the group consisting of H, optionally substituted C-Calkyl, alkenyl, or alkynyl group, and Ris a hydroxy, amino, alkoxy, alkylamino, optionally substituted C-Calkyl, alkenyl or alkynyl group; or the group —X—R, wherein X is —NH—, —O—, —S— or —N(alkyl)- and R' is hydrogen, an optionally substituted C-Calkyl, alkenyl, alkynyl, C-Ccycloalkyl, Rf(C-Ccycloalkyl), aryl, heterocyclyl, hetero C-Calkyl, arylalkylene, arylalkenylene, arylalkynylene, heteroaryl, cycloheteroalkyl, cycloheteroalkyl alkyl, or heteroarylalkylene, heteroarylalkenylene, heteroarylalkynylene group, the group —C(O)—R, —C(O)NRR, —SOR, or —NHC(O)R, wherein R, R, R, R, Rand Rhave the above meaning, andR7 is halogen, —NHNH, NHOH, NHCONH, guanylo (NH—C(NH)NH) or the group —X—R, wherein X has the above meaning and the meaning of Ris as defined for R.